Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
A new study sheds new light on the risks associated with the growing popularity of endoscopic resection in the treatment of localized, early-stage esophageal cancer.
A multi-institutional, randomized phase III trial of fractionation in locally advanced head and neck cancer demonstrated improved local-regional control and improved overall survival with no increase in late toxicity with hyperfractionated radiation therapy.
In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy were cancer-free 28 months after treatment. Side effects typical of standard radiation were also reduced in some cases.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|